Erin Talbert

You are here

Erin Talbert
Assistant Professor
Area:
Human Physiology
Specialization:
skeletal muscle wasting, cancer cache
End Degree:
PhD in Exercise Physiology
Institution:
University of Florida
Office:
1269B CBRB
Phone:
319-467-4667
Email: Laboratory:
Muscle Molecular Physiology
Lab Location:
1283 CBRB
Lab Phone:
319-467-4790
Lab Website:

Center Affiliations:

Holden Comprehensive Cancer Center and Fraternal Order of Eagles Diabetes Research Center

Courses Taught

  • HHP:4510 Energy Metabolism in Health and Disease
  • HHP:6400 Integrative Physiology Seminar

Research Interests

Healthy skeletal muscle is critical for activities of daily living and metabolic homeostasis, but a number of diseases can cause skeletal muscle wasting. Cancer-associated muscle wasting negatively impacts the quality of life of more than half of all cancer patients. Because muscle wasting in cancer patients is associated with poor outcomes, we’re particularly interested mechanisms driving skeletal muscle wasting and ways in which these losses can be prevented. We have a special interest in how pancreatic cancer causes muscle loss, as pancreatic cancer patients have the highest incidence and severity of muscle wasting. We’re also interested in the relationship between muscle wasting and diabetes in pancreatic cancer patients, as this seems to accelerate muscle wasting.

Recent Select Publications

Complete List of Dr. Talbert's Publications

Talbert EE, Cuitiño MC, Ladner KJ, Rajasekera PV, Siebert M, Shakya R, Leone GW, Ostrowski MC, Paleo B, Weisleder N, Reiser PJ, Webb A, Timmers CD, Eiferman DS, Evans DC, Dillhoff ME, Schmidt CR, Guttridge DC. “Modeling Human Cancer-induced Cachexia”. Cell Rep. 6;28(6):1612-1622 (2019).

Ramsey ML, Talbert E, Ahn D, Bekaii-Saab T, Badi N, Bloomston PM, Conwell DL, Cruz-Monserrate Z, Dillhoff M, Farren MR, Hinton A, Krishna SG, Lesinski GB, Mace T, Manilchuk A, Noonan A, Pawlik TM, Rajasekera PV, Schmidt C, Guttridge D, Hart PA. “Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer.” Pancreatology. S1424-3903(18)30747-6 (2018).

Talbert EE, Lewis HL, Farren MR, Ramsey ML, Chakedis JM, Rajasekera P, Haverick E, Sarna A, Bloomston M, Pawlik TM, Zimmers TA, Lesinski GB, Hart PA, Dillhoff ME, Schmidt CR, Guttridge DC. “Circulating MCP-1 is Associated with Cachexia in Treatment-Naïve Pancreatic Cancer Patients”. J Cachexia Sarcopenia Muscle. 9(2):358-368 (2018).

Talbert EE, Yang J, Mace TA, Farren MR, Farris AB, Young GS, Elnaggar O, Che Z, Timmers CD, Rajasekera P, Maskarinec JM, Bloomston M, Bekaii-Saab T, Guttridge DC, and Lesinski GB. “Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through Both Tumor Extrinsic and Intrinsic Activities” Mol Cancer Ther 16(2):344-356 (2017).